Surgical oncology

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the F

Retrieved on: 
Tuesday, February 27, 2024
Acquisition, Breast cancer, Neoplasm, Cancer, SSO, Forecasting, MD, ASCO, Growth, GM, American College of Neuropsychopharmacology, Surgical oncology, Myriad Genetics, Society, Capital expenditure, GAAP, Genetics, American College, Health, Patient, Public expenditure, Women's health, MCRR, IPG, Video game

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its fourth quarter and full-year ended December 31, 2023 and provided its outlook on business performance for its first quarter and full-year 2024.

Key Points: 
  • GAAP operating expenses in the fourth quarter of 2023 were $166.4 million, decreasing $9.7 million year-over-year.
  • Adjusted operating expenses in the fourth quarter of 2023 decreased $8.6 million year-over-year to $130.0 million, reflecting incremental cost control measures during the fourth quarter 2023.
  • GAAP operating loss in the fourth quarter of 2023 was $31.4 million, improving $20.8 million year-over-year; adjusted operating income in the fourth quarter of 2023 was $5.7 million, improving $19.6 million year-over-year from adjusted operating loss of $13.9 million in the fourth quarter of 2022.
  • Fourth quarter 2023 GAAP cash flow from operations was $(55) million; adjusted cash flow from operations in the fourth quarter of 2023 was $14 million, an increase of $10 million year-over-year.

Lumicell Announces Initial Data Demonstrating LUMISIGHT™’s Ability to Detect Tumors Metastasized to Multiple Organs in the Peritoneum

Retrieved on: 
Tuesday, February 20, 2024
Research, Medical Devices, Surgery, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Science, Oncology, Society, Survival, Massachusetts General Hospital, Peritoneum, Hospital, Optical flow, Peritoneal cavity, Surgical oncology, Associate, Patient, Dentistry

The ongoing study is utilizing the investigational LUMISIGHT optical imaging drug and accompanying imaging device to distinguish tumor metastases to organs within the peritoneum.

Key Points: 
  • The ongoing study is utilizing the investigational LUMISIGHT optical imaging drug and accompanying imaging device to distinguish tumor metastases to organs within the peritoneum.
  • “This data advances the potential for image-guided surgery to detect small tumors and metastases to organs in the peritoneal cavity which could provide better outcomes for our patients,” said Dr. Cusack.
  • “Further innovation is desperately needed to improve the benefits of cytoreductive surgery for this invasive and elusive cancer.
  • Everything we do at Lumicell is focused on improving surgical outcomes for patients,” said Howard Hechler, President of Lumicell.

Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Research Examining the High Rates of Re-Operations Following Breast-Conserving Surgeries and the Associated Increased Healthcare Costs

Retrieved on: 
Tuesday, February 20, 2024
Woman, Perimeter, BCS, University, OTC, Surgeon, PINK, Surgical oncology, Risk, MD Anderson Cancer Center, Attention, PMID, Medicare, Mastectomy, Conversion, Patient, Research

The results of our study demonstrate that high reoperation rates after breast-conserving surgery persist and are correlated with elevated risks and adverse outcomes for patients.

Key Points: 
  • The results of our study demonstrate that high reoperation rates after breast-conserving surgery persist and are correlated with elevated risks and adverse outcomes for patients.
  • I believe that these data underscore the need for new approaches to address high reoperation rates, including better methods of margin assessment for surgeons."
  • Funding to support this research was provided, in part, by Perimeter Medical Imaging AI, Inc.
    1 Kim Y, Ganduglia-Cazaban C, Tamirisa N, Lucci A, Krause TM.
  • Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery.

The Inner Circle Acknowledges, Hank C. Hill as a Pinnacle Life Member

Retrieved on: 
Monday, January 29, 2024
Surgical oncology, Philosophy, Neoplasm, Patient, Annals of Surgical Oncology, Research, Endocrine system, Sarcoma, Radiation, ABS, General surgery, Mentorship, Dance, Health, Multimedia, Knowledge, Music, Inner circle, Surgeon, National Research Service Award, Society, University, MD Anderson Cancer Center, Cancer, Skin, Gastrointestinal tract, Harlem Hospital Center, Esophagus, NIH, Liver, Stomach, Rectum, T-32, Morehouse School of Medicine, Breast, Tennis, Education, Publication, Pancreas, Endoscopy, Nursing

BROOKSVILLE, Fla., Jan. 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hank C. Hill is acknowledged as a Pinnacle Life Member for his contributions to the field of Surgical Oncology.

Key Points: 
  • BROOKSVILLE, Fla., Jan. 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hank C. Hill is acknowledged as a Pinnacle Life Member for his contributions to the field of Surgical Oncology.
  • Dr. Hill pursued higher education at the Brooklyn Campus of Long Island University where he earned his Bachelor of Science degree in Biology/Pre-Med.
  • Anderson Cancer Center in Houston, where he earned a surgical oncology research fellowship certificate in tumor biology.
  • Aside from his professional pursuits, Dr. Hill enjoys traveling, dancing (soca, reggae, reggaeton, R&B), and listening to music.

IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class

Retrieved on: 
Monday, January 29, 2024
Surgical oncology, Neoplasm, CentraState Medical Center, Breast imaging, SIO, DRS, Interventional radiology, Society, Breast cancer, Freezing, Oncology, Principal investigator, Education, ICE3, Radiation, Interventional oncology, Master Class, Physician, Medical imaging

This year's SIO meeting featured an educational event, Breast Cryoablation Master Class , the first of its kind by a radiology society.

Key Points: 
  • This year's SIO meeting featured an educational event, Breast Cryoablation Master Class , the first of its kind by a radiology society.
  • Interventional oncologists attending the half-day course learned from multidisciplinary experts in breast imaging, breast surgery, interventional radiology, surgical oncology, medical oncology, and radiation oncology.
  • A literature review of notable studies for breast cryoablation was presented, primarily including interim data from IceCure's ICE3 breast cancer cryoablation study, which demonstrated a 96.91% recurrence free rate.
  • Dr. Tomkovich commented, "The Master Class, which was filled to capacity, included interventional oncologists and breast radiologists seeking education to build a successful breast cryoablation program.

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

Retrieved on: 
Tuesday, January 9, 2024
Myriad Genetics, Patient, SSO, Health, ASCO, Gene, Breast cancer, Society, Genetics, Surgical oncology, Genetic testing, Cancer, Genetic counseling, Genomics, Penetrance, MYGN, PARP, Guideline, Diagnosis, Medicine, Medical device

SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.

Key Points: 
  • SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer.
  • Among the guidance includes:
    All patients with a current or previous diagnosis of invasive breast cancer ≤ 65 years should be offered BRCA1/2 testing.
  • Patients undergoing genetic testing should be given sufficient information before testing to provide informed consent.
  • “ASCO-SSO’s guideline update is an important step forward in advancing the use of genomics in clinical care for patients with breast cancer,” said Shelly Cummings, Vice President of Oncology Medical Affairs, Myriad Genetics.

SimBioSys and Mayo Clinic Enter Strategic Collaboration to Advance AI-powered Digital Precision Medicine Platform for Cancer Patients

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Research, Software, Artificial Intelligence, Hospitals, Surgery, Science, Melanoma, Surgical oncology, Quality of life, National Cancer Institute, Neoplasm, Medicine, Breast cancer, FDA, NCI-designated Cancer Center, Education, Heart, Cancer, AI, 3D, Mayo Clinic, Artificial intelligence, Genomics, Patient, Translational research, NCI, DCE, Skin, Medical imaging

SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine precision medicine for cancer, announced today it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients.

Key Points: 
  • SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine precision medicine for cancer, announced today it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients.
  • As part of the collaboration, SimBioSys has had access to and has been analyzing data from patients who participated in the Mayo Clinic-led BEAUTY clinical trial ( NCT02022202 ).
  • "SimBioSys complements current precision medicine techniques while only relying on readily available and previously acquired datasets such as imaging.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.

Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board

Retrieved on: 
Tuesday, December 5, 2023
Fibromatosis, Surgical oncology, Radiology, STS, AG, Treatment, ESSO, Drug development, Research, Editor-in-chief, Thermosome, CMO, Stromal cell, Bristol Myers Squibb, SSO, Therapy, ISG, BioNTech, Society, Sarcoma, Oncology, Hematology, Board certification, Senior, Pharmaceutical industry

Dr. Frank Hermann, MD, is a proficient clinical oncology professional with extensive experience in medical affairs, clinical research, and development.

Key Points: 
  • Dr. Frank Hermann, MD, is a proficient clinical oncology professional with extensive experience in medical affairs, clinical research, and development.
  • Prior to that, he was Senior Director Clinical Development Oncology at BioNTech SE and Chief Development Officer at 4SC AG.
  • Earlier in his career, Frank Hermann worked in medical affairs and clinical development at Bristol-Myers Squibb, most recently as Associate Medical Director Immuno-Oncology.
  • “We are very pleased that Frank is joining Thermosome as Chief Medical Officer,” said Dr. Pascal Schweizer, co-founder, and CEO/CFO of Thermosome.

Skanska signs additional contract to expand hospital in Portland, Oregon, USA, for USD 200M, about SEK 2.1 billion

Retrieved on: 
Friday, December 22, 2023
Patient, Hospital, Skanska, Surgical oncology

STOCKHOLM, Dec. 22, 2023 /PRNewswire/ -- Skanska has signed an additional contract with Oregon Health & Science University for its Hospital Expansion Project in Portland, Oregon, USA.

Key Points: 
  • STOCKHOLM, Dec. 22, 2023 /PRNewswire/ -- Skanska has signed an additional contract with Oregon Health & Science University for its Hospital Expansion Project in Portland, Oregon, USA.
  • The contract amendment is worth USD 200M, about SEK 2.1 billion, which will be included in the US order bookings for the fourth quarter of 2023.
  • The additional contract includes the interior build-out of the new hospital expansion.
  • The approximately 50,000 square meter (533,000-SF), 14-story hospital expansion will be executed within a collaborative project delivery model.

Hybrid Operating Room Equipment Global Market Report 2023 - Market Revenue Data for 2022-2023, Forecasts for 2024 and 2026 and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 28, 2023
Surgery, Health, Medical Devices, HOR, Cardiology, Health Promotion International, Mortality, Application, Cardiovascular disease, Neurology, Death, Intelligence, USD, Khors, Chronic condition, Component, Instrument, Insight, Communication, Growth, MRI, Environment, Surgical oncology, ESG

A hybrid operating room is adopted mainly for complex cardiovascular, neurological, orthopedic, and other surgeries.

Key Points: 
  • A hybrid operating room is adopted mainly for complex cardiovascular, neurological, orthopedic, and other surgeries.
  • Rapid technological development and demand for open and minimally invasive surgeries are the key factors driving the growth of the global hybrid operating room market.
  • Further, companies are looking to develop advanced technology to maintain their position within the global market.
  • For market estimates, data has been provided for 2022 as the base year, with forecasts for 2023 through 2028.